The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the…
Thoracic surgeon Dr. Bryan Burt at the Baylor College of Medicine wants to better identify which patients with pleural mesothelioma cancer will benefit (and…
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors.
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and…
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a…
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up…
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Reviewed & Fact-Checked
This page was reviewed by:
Fact-checked and verified content:
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
